Literature DB >> 26239089

Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.

Sophie Bernard1, Lauriane Goldwirt2, Sandy Amorim1, Pauline Brice3, Josette Brière4, Eric de Kerviler5, Samia Mourah6, Hélène Sauvageon2, Catherine Thieblemont1.   

Abstract

The risk of central nervous system (CNS) dissemination in mantle cell lymphoma (MCL) is low and occurs late in the course of the disease. However, prognosis in such cases remains extremely poor despite high-dose antimetabolite chemotherapy. Among novel drugs used to treat relapsing MCL patients, ibrutinib, an oral inhibitor of Bruton tyrosine kinase, shows great promise. Here we report the clinical observation of 3 MCL patients with symptomatic CNS relapse treated with single-agent ibrutinib. All 3 patients had dramatic and rapid responses with almost immediate recovery from symptoms. We also confirmed that ibrutinib crosses the blood-brain barrier with parallel pharmacokinetic analyses in plasma and cerebrospinal fluid using a validated LC-MS/MS method. All responses were ongoing after 2 months to 1 year of follow-up.
© 2015 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26239089      PMCID： PMC4591793          DOI： 10.1182/blood-2015-05-647834

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  13 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 2.  Mantle cell lymphoma: evolving management strategies.

Authors:  Elias Campo; Simon Rule
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

3.  Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center.

Authors:  Agustin Avilés; M Jesús Nambo; Natividad Neri
Journal:  Med Oncol       Date:  2013-03-01       Impact factor: 3.064

4.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

5.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

6.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

7.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Authors:  Michael L Wang; Kristie A Blum; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Liang Zhang; Linda Baher; Mei Cheng; Dana Lee; Darrin M Beaupre; Simon Rule
Journal:  Blood       Date:  2015-06-09       Impact factor: 22.113

8.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

Review 10.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716
View more
  49 in total

Review 1.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

2.  Identifying targetable genetic features in primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Int J Hematol Oncol       Date:  2017-01-13

3.  Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.

Authors:  Mark Plander; Tamás Szendrei; Árpád Vadvári; János Iványi
Journal:  Pathol Oncol Res       Date:  2018-10-25       Impact factor: 3.201

4.  First-line ibrutinib for Bing-Neel syndrome.

Authors:  Aaron Tallant; Daniel Selig; Sam O Wanko; Joseph Roswarski
Journal:  BMJ Case Rep       Date:  2018-10-02

5.  Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.

Authors:  Yu Shi; Olga A Guryanova; Wenchao Zhou; Chong Liu; Zhi Huang; Xiaoguang Fang; Xiuxing Wang; Cong Chen; Qiulian Wu; Zhicheng He; Wei Wang; Wei Zhang; Tao Jiang; Qing Liu; Yaping Chen; Wenying Wang; Jingjing Wu; Leo Kim; Ryan C Gimple; Hua Feng; Hsiang-Fu Kung; Jennifer S Yu; Jeremy N Rich; Yi-Fang Ping; Xiu-Wu Bian; Shideng Bao
Journal:  Sci Transl Med       Date:  2018-05-30       Impact factor: 17.956

6.  Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema.

Authors:  Sumeet P Mirgh; Rayaz Ahmed; Narendra Agrawal; Sneha Bothra; Bhaarat Mohan; Ambar Garg; Shinto Francis Thekkudan; Vishvdeep Khushoo; Dinesh Bhurani
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-13       Impact factor: 0.900

7.  Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.

Authors:  Fateeha Furqan; Grace Watson; Felipe Samaniego; Luis E Fayad; Michael W Morrison; Philip A Thompson; Raphael E Steiner; Linda Chi; Bouthaina Dabaja; Chelsea C Pinnix; Sattva S Neelapu; Loretta J Nastoupil; Paolo Strati
Journal:  Leuk Lymphoma       Date:  2020-07-10

8.  Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.

Authors:  Simon Rule; Martin Dreyling; Andre Goy; Georg Hess; Rebecca Auer; Brad Kahl; Nora Cavazos; Black Liu; Shiyi Yang; Fong Clow; Jenna D Goldberg; Darrin Beaupre; Jessica Vermeulen; Mark Wildgust; Michael Wang
Journal:  Br J Haematol       Date:  2017-08-18       Impact factor: 6.998

Review 9.  Biology of CNS lymphoma and the potential of novel agents.

Authors:  James L Rubenstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

10.  Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Authors:  Monique C Minnema; Eva Kimby; Shirley D'Sa; Luc-Matthieu Fornecker; Stéphanie Poulain; Tom J Snijders; Efstathios Kastritis; Stéphane Kremer; Aikaterini Fitsiori; Laurence Simon; Frédéric Davi; Michael Lunn; Jorge J Castillo; Christopher J Patterson; Magali Le Garff-Tavernier; Myrto Costopoulos; Véronique Leblond; Marie-José Kersten; Meletios A Dimopoulos; Steven P Treon
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.